Management der akuten myeloischen Leukämie im höheren Alter

 

 Buy Article Permissions and Reprints

Publication History

Article published online:
02 May 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

• Literatur

• 1 Ferrara F, Barosi G, Venditti A. et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia 2013; 27: 997-999
  CrossrefPubMedSearch in Google Scholar
• 2 Apolito V, Arrigo G, Vasseur L. et al. Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax. British Journal of Haematology 2023; 203: e98-e101
  CrossrefPubMedSearch in Google Scholar
• 3 Venditti A, Cairoli R, Caira M. et al. Assessing eligibility for treatment in acute myeloid leukemia in 2023. Expert Review of Hematology 2023; 16: 181-190
  CrossrefPubMedSearch in Google Scholar
• 4 Bellera CA, Rainfray M, Mathoulin-Pélissier S. et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Annals of Oncology 2012; 23: 2166-2172
  CrossrefPubMedSearch in Google Scholar
• 5 Sorror ML, Storer BE, Fathi AT. et al. Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality. JAMA Oncology 2017; 3: 1675-1682
  CrossrefPubMedSearch in Google Scholar
• 6 Jahn E, Saadati M, Fenaux P. et al. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia 2023; 37: 2187-2196
  CrossrefPubMedSearch in Google Scholar
• 7 Tsai XCH, Sun KJ, Lo MY. et al. Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood Cancer J 2023; 13: 1-11
  CrossrefPubMedSearch in Google Scholar
• 8 Lazarevic V, Hörstedt AS, Johansson B. et al. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer Journal 2014; 4: e188-e188
  CrossrefPubMedSearch in Google Scholar
• 9 Silva P, Neumann M, Schroeder MP. et al. Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape. Leukemia 2017; 31: 1640-1644
  CrossrefPubMedSearch in Google Scholar
• 10 Metzeler KH, Herold T, Rothenberg-Thurley M. et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. American Society of Hematology. Accessed November 06, 2024 at: https://ashpublications.org/blood/article/128/5/686/35562/Spectrum-and-prognostic-relevance-of-driver-gene
  PubMed
• 11 Akute Myeloische Leukämie (AML). Onkopedia. Accessed November 06, 2024 at: https://www.onkopedia.com/de/onkopedia/guidelines/akute-myeloische-leukaemie-aml
  PubMed
• 12 Arber DA, Orazi A, Hasserjian RP. et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140: 1200-1228
  CrossrefPubMedSearch in Google Scholar
• 13 Khoury JD, Solary E, Abla O. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36: 1703-1719
  CrossrefPubMedSearch in Google Scholar
• 14 Huber S, Baer C, Hutter S. et al. AML classification in the year 2023: How to avoid a Babylonian confusion of languages. Leukemia 2023; 37: 1413-1420
  CrossrefPubMedSearch in Google Scholar
• 15 Molica M, Perrone S, Mazzone C. et al. CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML. Cancers 2022; 14: 2843
  CrossrefPubMedSearch in Google Scholar
• 16 Lancet JE, Uy GL, Newell LF. et al. Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML. Journal of Clinical Oncology. Accessed November 06, 2024 at: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.7510
  PubMed
• 17 Lindsley RC, Gibson CJ, Murdock HM. et al. Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). Blood 2019; 134: 15
  CrossrefPubMedSearch in Google Scholar
• 18 Döhner H, Wei AH, Appelbaum FR. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140: 1345-1377
  CrossrefPubMedSearch in Google Scholar
• 19 Stone RM, Mandrekar Sumithra J, Sanford BL. et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. New England Journal of Medicine 2017; 377: 454-464
  CrossrefPubMedSearch in Google Scholar
• 20 Erba HP, Montesinos P, Kim HJ. et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2023; 401: 1571-1583
  CrossrefPubMedSearch in Google Scholar
• 21 Döhner H, Weber D, Krzykalla J. et al. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Advances 2022; 6: 5345-5355
  CrossrefPubMedSearch in Google Scholar
• 22 Hills RK, Castaigne S, Appelbaum FR. et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. The Lancet Oncology 2014; 15: 986-996
  CrossrefPubMedSearch in Google Scholar
• 23 Richardson PG, Corbacioglu S. Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer J 2020; 10: 1-5
  CrossrefPubMedSearch in Google Scholar
• 24 Lambert J, Pautas C, Terré C. et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 2018; 104: 113
  CrossrefPubMedSearch in Google Scholar
• 25 Cortes JE, de Lima M, Dombret H. et al. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol 2020; 13: 137
  CrossrefPubMedSearch in Google Scholar
• 26 Döhner H, Weber D, Krzykalla J. et al. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial. The Lancet Haematology 2023; 10: e495-e509
  CrossrefPubMedSearch in Google Scholar
• 27 Wei AH, Döhner H, Pocock C. et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. New England Journal of Medicine 2020; 383: 2526-2537
  CrossrefPubMedSearch in Google Scholar
• 28 Burchert A, Bug G, Fritz LV. et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN). JCO 2020; 38: 2993-3002
  CrossrefPubMedSearch in Google Scholar
• 29 DiNardo CD, Jonas BA, Pullarkat V. et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine 2020; 383: 617-629
  CrossrefPubMedSearch in Google Scholar
• 30 Fowler-Shorten DJ, Maynard RS, Hampton K. et al. Acute myeloid leukemia-driven IL-3-dependent upregulation of BCL2 in non-malignant hematopoietic stem and progenitor cells increases venetoclax-induced cytopenias. Haematologica 2024; 109: 1576
  CrossrefPubMedSearch in Google Scholar
• 31 Döhner H, Pratz KW, DiNardo CD. et al. ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine. Blood 2022; 140: 1441-1444
  CrossrefPubMedSearch in Google Scholar
• 32 Döhner H, DiNardo CD, Appelbaum F. et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 2024; blood.2024025409
  CrossrefPubMedSearch in Google Scholar
• 33 Pollyea DA, Pratz KW, Wei AH. et al. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clinical Cancer Research 2022; 28: 5272-5279
  CrossrefPubMedSearch in Google Scholar
• 34 Alber D, Rummelt C, Strüßmann T. et al. Single-Center Experience of Decitabine/Venetoclax in Newly Diagnosed Older AML Patients with Non-Favorable Genetics: Bridging to Allo-HCT or Treatment Continuation. Blood 2023; 142: 7091
  CrossrefPubMedSearch in Google Scholar
• 35 Karrar O, Abdelmagid M, Rana M. et al. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. Am J Hematol 2024; 99: E63-E66
  CrossrefPubMedSearch in Google Scholar
• 36 Montesinos P, Recher C, Vives S. et al. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. New England Journal of Medicine 2022; 386: 1519-1531
  CrossrefPubMedSearch in Google Scholar
• 37 Bhatt A, Powell K, Prasad V. The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?. Translational Oncology 2022; 25
  CrossrefPubMedSearch in Google Scholar
• 38 Dombret H, Seymour JF, Butrym A. et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015; 126: 291-299
  CrossrefPubMedSearch in Google Scholar
• 39 Lübbert M, Wijermans PW, Kicinski M. et al. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. The Lancet Haematology 2023; 10: e879-e889
  CrossrefPubMedSearch in Google Scholar
• 40 Zeidan AM, Fenaux P, Gobbi M. et al. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood 2022; 140: 285-289
  CrossrefPubMedSearch in Google Scholar
• 41 Garcia-Manero G, McCloskey J, Griffiths EA. et al. Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. The Lancet Haematology 2024; 11: e15-e26
  CrossrefPubMedSearch in Google Scholar